Magnesium Counteracts Vascular Calcification: Passive Interference or Active Modulation?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 37, Issue 8, 2017, Pages 1431-1445

  Ter Braake, Anique D ^a   Shanahan, Catherine M ^b   De Baaij, Jeroen H F ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

cardiovascular diseases; chronic kidney disease; magnesium; vascular calcification

Indexed keywords

CALCIUM; CALCIUM PHOSPHATE; HYDROXYAPATITE; MAGNESIUM; PHOSPHATE;

ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL WALL; BONE DEVELOPMENT; CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL TRANSDIFFERENTIATION; CIRCULATION; DIABETES MELLITUS; HEART ARRHYTHMIA; HOMEOSTASIS; HYPERTENSION; INTESTINE; MODULATION; PHENOTYPE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; VASCULAR SMOOTH MUSCLE; VASCULAR SMOOTH MUSCLE CELL; ANIMAL; BLOOD; CHRONIC KIDNEY FAILURE; COMPLICATION; FEMALE; HUMAN; KIDNEY; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; SMOOTH MUSCLE CELL; VASCULAR CALCIFICATION;

ANIMALS; CALCIUM PHOSPHATES; CELL TRANSDIFFERENTIATION; FEMALE; HOMEOSTASIS; HUMANS; INTESTINES; KIDNEY; MAGNESIUM; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOGENESIS; PHENOTYPE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; VASCULAR CALCIFICATION;

EID: 85021642693     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.117.309182     Document Type: Review

References (189)

1. Foley RN, Parfrey PS. Cardiovascular disease and mortality in ESRD. J Nephrol. 1998;11:239-245.
2. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2016 update. Circulation. 2016;133:447-454.
3. Saran R, Li Y, Robinson B. US Renal Data System 2015 Annual Data Report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2014;67:S1-S434.
4. Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014-1021.
5. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis. 1996;27:394-401.
6. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483. doi: 10.1056/NEJM200005183422003.
7. Budoff MJ, Rader DJ, Reilly MP, Mohler ER III, Lash J, Yang W, Rosen L, Glenn M, Teal V, Feldman HI; CRIC Study Investigators. Relationship of estimated GFR and coronary artery calcification in the CRIC (Chronic Renal Insufficiency Cohort) Study. Am J Kidney Dis. 2011;58:519-526. doi: 10.1053/j.ajkd.2011.04.024.
8. Floege J, Ketteler M. Vascular calcification in patients with end-stage renal disease. Nephrol Dial Transplant. 2004;19(suppl 5):V59-V66. doi: 10.1093/ndt/gfh1058.
9. London GM, Guérin AP, Marchais SJ, Métivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003;18:1731-1740.
10. Massy ZA, Drüeke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J. 2012;5(suppl 1):i52-i61. doi: 10.1093/ndtplus/sfr167.
11. de Baaij JHF, Hoenderop JGJ, Bindels RJM. Magnesium in man: implications for health and disease. Physiol Rev. 2015;95:1-46.
12. Graham LA, Caesar JJ, Burgen AS. Gastrointestinal absorption and excretion of Mg 28 in man. Metabolism. 1960;9:646-659.
13. Alfrey AC, Miller NL, Trow R. Effect of age and magnesium depletion on bone magnesium pools in rats. J Clin Invest. 1974;54:1074-1081. doi: 10.1172/JCI107851.
14. Thebault S, Alexander RT, Tiel Groenestege WM, Hoenderop JG, Bindels RJ. EGF increases TRPM6 activity and surface expression. J Am Soc Nephrol. 2009;20:78-85. doi: 10.1681/ASN.2008030327.
15. Nair AV, Hocher B, Verkaart S, van Zeeland F, Pfab T, Slowinski T, Chen YP, Schlingmann KP, Schaller A, Gallati S, Bindels RJ, Konrad M, Hoenderop JG. Loss of insulin-induced activation of TRPM6 magnesium channels results in impaired glucose tolerance during pregnancy. Proc Natl Acad Sci USA. 2012;109:11324-11329. doi: 10.1073/pnas.1113811109.
16. Li M, Du J, Jiang J, Ratzan W, Su LT, Runnels LW, Yue L. Molecular determinants of Mg2+ and Ca2+ permeability and pH sensitivity in TRPM6 and TRPM7. J Biol Chem. 2007;282:25817-25830. doi: 10.1074/jbc.M608972200.
17. de Baaij JH, Blanchard MG, Lavrijsen M, Leipziger J, Bindels RJ, Hoenderop JG. P2X4 receptor regulation of transient receptor potential melastatin type 6 (TRPM6) Mg2+ channels. Pflugers Arch. 2014;466:1941-1952. doi: 10.1007/s00424-014-1440-3.
18. Blanchard MG, De Baaij JHF, Verkaart SAJ, et al. Flavaglines stimulate transient receptor potential melastatin type 6 (TRPM6) channel activity. PLoS One. 2015;10:e0119028.
19. Quamme GA, Wong NL, Dirks JH, Roinel N, De Rouffignac C, Morel F. Magnesium handling in the dog kidney: a micropuncture study. Pflugers Arch. 1978;377:95-99.
20. Voets T, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ, Hoenderop JG. TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem. 2004;279:19-25. doi: 10.1074/jbc.M311201200.
21. Kolisek M, Nestler A, Vormann J, Schweigel-Röntgen M. Human gene SLC41A1 encodes for the Na+/Mg2+ exchanger. Am J Physiol Cell Physiol. 2012;302:C318-C326. doi: 10.1152/ajpcell.00289.2011.
22. de Baaij JHF, Arjona FJ, van den Brand M, et al. Identification of SLC41A3 as a novel player in magnesium homeostasis. Sci Rep. 2016;6:28565.
23. Dewitte K, Dhondt A, Giri M, Stöckl D, Rottiers R, Lameire N, Thienpont LM. Differences in serum ionized and total magnesium values during chronic renal failure between nondiabetic and diabetic patients: a crosssectional study. Diabetes Care. 2004;27:2503-2505.
24. Coburn JW, Popovtzer MM, Massry SG, Kleeman CR. The physicochemical state and renal handling of divalent ions in chronic renal failure. Arch Intern Med. 1969;124:302-311.
25. de Roij van Zuijdewijn CL, Grooteman MP, Bots ML, Blankestijn PJ, Steppan S, Büchel J, Groenwold RH, Brandenburg V, van den Dorpel MA, Ter Wee PM, Nubé MJ, Vervloet MG. Serum magnesium and sudden death in European hemodialysis patients. PLoS One. 2015;10:e0143104. doi: 10.1371/journal.pone.0143104.
26. Cunningham J, Rodríguez M, Messa P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. CKJ Clin Kidney J. 2012;5:i39-i51.
27. Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6:913-921. doi: 10.2215/CJN.06040710.
28. Blumberg D, Bonetti A, Jacomella V, Capillo S, Truttmann AC, Lüthy CM, Colombo JP, Bianchetti MG. Free circulating magnesium and renal magnesium handling during acute metabolic acidosis in humans. Am J Nephrol. 1998;18:233-236. doi: 13342.
29. Elin RJ. Assessment of magnesium status for diagnosis and therapy. Magnes Res. 2010;23:S194-S198. doi: 10.1684/mrh.2010.0213.
30. Mikolasevic I, Milic S, Stimac D, Zaputovic L, Lukenda Zanko V, Gulin T, Jakopcic I, Klaric D, Gulin M, Orlic L. Is there a relationship between hypomagnesemia and proton-pump inhibitors in patients on chronic hemodialysis? Eur J Intern Med. 2016;30:99-103. doi: 10.1016/j. ejim.2016.01.026.
31. Nakashima A, Ohkido I, Yokoyama K, Mafune A, Urashima M, Yokoo T. Proton pump inhibitor use and magnesium concentrations in hemodialysis patients: a cross-sectional study. PLoS One. 2015;10:e0143656.
32. Sakaguchi Y, Shoji T, Hayashi T, Suzuki A, Shimizu M, Mitsumoto K, Kawabata H, Niihata K, Okada N, Isaka Y, Rakugi H, Tsubakihara Y. Hypomagnesemia in type 2 diabetic nephropathy: a novel predictor of end-stage renal disease. Diabetes Care. 2012;35:1591-1597. doi: 10.2337/dc12-0226.
33. Gommers LM, Hoenderop JG, Bindels RJ, de Baaij JH. Hypomagnesemia in type 2 diabetes: a vicious circle? Diabetes. 2016;65:3-13. doi: 10.2337/ db15-1028.
34. Sakaguchi Y, Fujii N, Shoji T, Hayashi T, Rakugi H, Isaka Y. Hypomagnesemia is a significant predictor of cardiovascular and noncardiovascular mortality in patients undergoing hemodialysis. Kidney Int. 2014;85:174-181. doi: 10.1038/ki.2013.327.
35. Cai K, Luo Q, Dai Z, et al. Hypomagnesemia is associated with increased mortality among peritoneal dialysis patients. PLoS One. 2016;11:e0152488.
36. Li L, Streja E, Rhee CM, Mehrotra R, Soohoo M, Brunelli SM, Kovesdy CP, Kalantar-Zadeh K. Hypomagnesemia and mortality in incident hemodialysis patients. Am J Kidney Dis. 2015;66:1047-1055.
37. Guasch-Ferré M, Bulló M, Estruch R, et al; PREDIMED Study Group. Dietary magnesium intake is inversely associated with mortality in adults at high cardiovascular disease risk. J Nutr. 2014;144:55-60. doi: 10.3945/ jn.113.183012.
38. Fang X, Wang K, Han D, He X, Wei J, Zhao L, Imam MU, Ping Z, Li Y, Xu Y, Min J, Wang F. Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies. BMC Med. 2016;14:210. doi: 10.1186/s12916-016-0742-z.
39. Lutsey PL, Alonso A, Michos ED, et al. Serum magnesium, phosphorus, and calcium are associated with risk of incident heart failure: the Atherosclerosis Risk in Communities (ARIC). Am J Clin Nutr. 2014;100:756-764.
40. Kieboom BCT, Niemeijer MN, Leening MJG, et al. Serum magnesium and the risk of death from coronary heart disease and sudden cardiac death. J Am Heart Assoc. 2016;5:e002707.
41. Gartside PS, Glueck CJ. The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: the prospective NHANES I follow-up study. J Am Coll Nutr. 1995;14:71-79.
42. Marniemi J, Järvisalo J, Toikka T, Räihä I, Ahotupa M, Sourander L. Blood vitamins, mineral elements and inflammation markers as risk factors of vascular and non-vascular disease mortality in an elderly population. Int J Epidemiol. 1998;27:799-807.
43. Liao F, Folsom AR, Brancati FL. Is low magnesium concentration a risk factor for coronary heart disease? The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 1998;136:480-490.
44. Ford ES. Serum magnesium and ischaemic heart disease: findings from a national sample of US adults. Int J Epidemiol. 1999;28:645-651.
45. Leone N, Courbon D, Ducimetiere P, Zureik M. Zinc, copper, and magnesium and risks for all-cause, cancer, and cardiovascular mortality. Epidemiology. 2006;17:308-314. doi: 10.1097/01.ede.0000209454.41466.b7.
46. Ohira T, Peacock JM, Iso H, Chambless LE, Rosamond WD, Folsom AR. Serum and dietary magnesium and risk of ischemic stroke: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2009;169:1437-1444. doi: 10.1093/aje/kwp071.
47. Khan AM, Sullivan L, McCabe E, Levy D, Vasan RS, Wang TJ. Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J. 2010;160:715-720. doi: 10.1016/j. ahj.2010.06.036.
48. Peacock JM, Ohira T, Post W, Sotoodehnia N, Rosamond W, Folsom AR. Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010;160:464-470. doi: 10.1016/j.ahj.2010.06.012.
49. Reffelmann T, Ittermann T, Dörr M, Völzke H, Reinthaler M, Petersmann A, Felix SB. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis. 2011;219:280-284. doi: 10.1016/j.atherosclerosis.2011.05.038.
50. Chiuve SE, Korngold EC, Januzzi JL Jr, Gantzer ML, Albert CM. Plasma and dietary magnesium and risk of sudden cardiac death in women. Am J Clin Nutr. 2011;93:253-260. doi: 10.3945/ajcn.110.002253.
51. Feng P, Niu X, Hu J, Zhou M, Liang H, Zhang Y, Tong W, Xu T. Relationship of serum magnesium concentration to risk of short-term outcome of acute ischemic stroke. Blood Press. 2013;22:297-301. doi: 10.3109/08037051.2012.759696.
52. Khan AM, Lubitz SA, Sullivan LM, Sun JX, Levy D, Vasan RS, Magnani JW, Ellinor PT, Benjamin EJ, Wang TJ. Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation. 2013;127:33-38. doi: 10.1161/ CIRCULATIONAHA.111.082511.
53. Misialek JR, Lopez FL, Lutsey PL, Huxley RR, Peacock JM, Chen LY, Soliman EZ, Agarwal SK, Alonso A. Serum and dietary magnesium and incidence of atrial fibrillation in whites and in African Americans-Atherosclerosis Risk in Communities (ARIC) study. Circ J. 2013;77:323-329.
54. Joosten MM, Gansevoort RT, Mukamal KJ, van der Harst P, Geleijnse JM, Feskens EJ, Navis G, Bakker SJ; PREVEND Study Group. Urinary and plasma magnesium and risk of ischemic heart disease. Am J Clin Nutr. 2013;97:1299-1306. doi: 10.3945/ajcn.112.054114.
55. Akarolo-Anthony SN, Jiménez MC, Chiuve SE, Spiegelman D, Willett WC, Rexrode KM. Plasma magnesium and risk of ischemic stroke among women. Stroke. 2014;45:2881-2886. doi: 10.1161/ STROKEAHA.114.005917.
56. Lee SY, Hyun YY, Lee KB, Kim H. Low serum magnesium is associated with coronary artery calcification in a Korean population at low risk for cardiovascular disease. Nutr Metab Cardiovasc Dis. 2015;25:1056-1061. doi: 10.1016/j.numecd.2015.07.010.
57. Markovits N, Kurnik D, Halkin H, Margalit R, Bialik M, Lomnicky Y, Loebstein R. Database evaluation of the association between serum magnesium levels and the risk of atrial fibrillation in the community. Int J Cardiol. 2016;205:142-146. doi: 10.1016/j.ijcard.2015.12.014.
58. Posadas-Sánchez R, Posadas-Romero C, Cardoso-Saldaña G, Vargas-Alarcón G, Villarreal-Molina MT, Pérez-Hernández N, Rodríguez-Pérez JM, Medina-Urrutia A, Jorge-Galarza E, Juárez-Rojas JG, Torres-Tamayo M. Serum magnesium is inversely associated with coronary artery calcification in the Genetics of Atherosclerotic Disease (GEA) study. Nutr J. 2016;15:22. doi: 10.1186/s12937-016-0143-3.
59. Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int. 1987;32:388-394.
60. Tzanakis I, Virvidakis K, Tsomi A, Mantakas E, Girousis N, Karefyllakis N, Papadaki A, Kallivretakis N, Mountokalakis T. Intra-and extracellular magnesium levels and atheromatosis in haemodialysis patients. Magnes Res. 2004;17:102-108.
61. Ishimura E, Okuno S, Yamakawa T, Inaba M, Nishizawa Y. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res. 2007;20:237-244.
62. Ishimura E, Okuno S, Kitatani K, Tsuchida T, Yamakawa T, Shioi A, Inaba M, Nishizawa Y. Significant association between the presence of peripheral vascular calcification and lower serum magnesium in hemodialysis patients. Clin Nephrol. 2007;68:222-227.
63. Kanbay M, Yilmaz MI, Apetrii M, Saglam M, Yaman H, Unal HU, Gok M, Caglar K, Oguz Y, Yenicesu M, Cetinkaya H, Eyileten T, Acikel C, Vural A, Covic A. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients. Am J Nephrol. 2012;36:228-237. doi: 10.1159/000341868.
64. João Matias P, Azevedo A, Laranjinha I, Navarro D, Mendes M, Ferreira C, Amaral T, Jorge C, Aires I, Gil C, Ferreira A. Lower serum magnesium is associated with cardiovascular risk factors and mortality in haemodialysis patients. Blood Purif. 2014;38:244-252. doi: 10.1159/000366124.
65. Yu L, Li H, Wang SX. Serum magnesium and mortality in maintenance hemodialysis patients. Blood Purif. 2017;43:31-36. doi: 10.1159/000451052.
66. Molnar AO, Biyani M, Hammond I, Harmon JP, Lavoie S, McCormick B, Sood MM, Wagner J, Pena E, Zimmerman DL. Lower serum magnesium is associated with vascular calcification in peritoneal dialysis patients: a cross sectional study. BMC Nephrol. 2017;18:129. doi: 10.1186/s12882-017-0549-y.
67. Qu X, Jin F, Hao Y, et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS One. 2013;8:e57720.
68. Del Gobbo LC, Imamura F, Wu JH, de Oliveira Otto MC, Chiuve SE, Mozaffarian D. Circulating and dietary magnesium and risk of cardiovascular disease: a systematic review and meta-analysis of prospective studies. Am J Clin Nutr. 2013;98:160-173. doi: 10.3945/ajcn.112.053132.
69. Costello RB, Elin RJ, Rosanoff A, Wallace TC, Guerrero-Romero F, Hruby A, Lutsey PL, Nielsen FH, Rodriguez-Moran M, Song Y, Van Horn LV. Perspective: the case for an evidence-based reference interval for serum magnesium: the time has come. Adv Nutr. 2016;7:977-993. doi: 10.3945/an.116.012765.
70. Lowenstein FW, Stanton MF. Serum magnesium levels in the United States, 1971-1974. J Am Coll Nutr. 1986;5:399-414.
71. Angkananard T, Anothaisintawee T, Eursiriwan S, Gorelik O, McEvoy M, Attia J, Thakkinstian A. The association of serum magnesium and mortality outcomes in heart failure patients: a systematic review and meta-analysis. Medicine. 2016;95:e5406. doi: 10.1097/MD.0000000000005406.
72. Agus ZS, Morad M. Modulation of cardiac ion channels by magnesium. Annu Rev Physiol. 1991;53:299-307. doi: 10.1146/annurev. ph.53.030191.001503.
73. Kulick DL, Hong R, Ryzen E, Rude RK, Rubin JN, Elkayam U, Rahimtoola SH, Bhandari AK. Electrophysiologic effects of intravenous magnesium in patients with normal conduction systems and no clinical evidence of significant cardiac disease. Am Heart J. 1988;115:367-373.
74. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, Stern S. Treatment of torsade de pointes with magnesium sulfate. Circulation. 1988;77:392-397.
75. Ho KM. Intravenous magnesium for cardiac arrhythmias: jack of all trades. Magnes Res. 2008;21:65-68.
76. Ho KM, Sheridan DJ, Paterson T. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. Heart. 2007;93:1433-1440. doi: 10.1136/hrt.2006.111492.
77. Kotecha D. Magnesium for atrial fibrillation, myth or magic? Circ Arrhythmia Electrophysiol. 2016;9:1-4.
78. Maier JAM. Endothelial cells and magnesium: implications in atherosclerosis. Clin Sci. 2011;122:397-407.
79. Matsushita K, Sang Y, Ballew SH, Shlipak M, Katz R, Rosas SE, Peralta CA, Woodward M, Kramer HJ, Jacobs DR, Sarnak MJ, Coresh J. Subclinical atherosclerosis measures for cardiovascular prediction in CKD. J Am Soc Nephrol. 2015;26:439-447. doi: 10.1681/ASN.2014020173.
80. Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediaterisk individuals. JAMA. 2012;308:788-795. doi: 10.1001/jama.2012.9624.
81. Vervloet M, Cozzolino M. Vascular calcification in chronic kidney disease: different bricks in the wall? Kidney Int. 2016;91:808-817.
82. Sakaguchi Y, Hamano T, Nakano C, et al. Association between density of coronary artery calcification and serum magnesium levels among patients with chronic kidney disease. PLoS One. 2016;11:e0163673. doi: 10.1371/ journal.pone.0163673.
83. Tzanakis I, Pras A, Kounali D, Mamali V, Kartsonakis V, Mayopoulou-Symvoulidou D, Kallivretakis N. Mitral annular calcifications in haemodialysis patients: a possible protective role of magnesium. Nephrol Dial Transplant. 1997;12:2036-2037.
84. Paula Silva A, Fragoso A, Silva C, et al. Magnesium and mortality in patients with diabetes and early chronic kidney disease. J Diabetes Metab. 2014;5:1-6.
85. Ferrè S, Baldoli E, Leidi M, Maier JA. Magnesium deficiency promotes a pro-atherogenic phenotype in cultured human endothelial cells via activation of NFkB. Biochim Biophys Acta. 2010;1802:952-958. doi: 10.1016/j. bbadis.2010.06.016.
86. Maier JAM. Low magnesium and atherosclerosis: an evidence-based link. Mol Aspects Med. 2003;24:137-146.
87. Cohen H, Sherer Y, Shaish A, Shoenfeld Y, Levkovitz H, Bitzur R, Harats D. Atherogenesis inhibition induced by magnesium-chloride fortification of drinking water. Biol Trace Elem Res. 2002;90:251-259. doi: 10.1385/ BTER:90:1-3:251.
88. Sherer Y, Shoenfeld Y, Shaish A, Levkovitz H, Bitzur R, Harats D. Suppression of atherogenesis in female low-density lipoprotein receptor knockout mice following magnesium fortification of drinking water: the importance of diet. Pathobiology. 2000;68:93-98. doi: 28119.
89. Ravn HB, Korsholm TL, Falk E. Oral magnesium supplementation induces favorable antiatherogenic changes in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2001;21:858-862.
90. Paravicini TM, Yogi A, Mazur A, Touyz RM. Dysregulation of vascular TRPM7 and annexin-1 is associated with endothelial dysfunction in inherited hypomagnesemia. Hypertension. 2009;53:423-429. doi: 10.1161/HYPERTENSIONAHA.108.124651.
91. Shivakumar K, Kumar BP. Magnesium deficiency enhances oxidative stress and collagen synthesis in vivo in the aorta of rats. Int J Biochem Cell Biol. 1997;29:1273-1278.
92. Pagès N, Gogly B, Godeau G, Igondjo-Tchen S, Maurois P, Durlach J, Bac P. Structural alterations of the vascular wall in magnesium-deficient mice. A possible role of gelatinases A (MMP-2) and B (MMP-9). Magnes Res. 2003;16:43-48.
93. Jiang Q, Uitto J. Restricting dietary magnesium accelerates ectopic connective tissue mineralization in a mouse model of pseudoxanthoma elasticum (Abcc6(-/-)). Exp Dermatol. 2012;21:694-699. doi: 10.1111/j.1600-0625.2012.01553.x.
94. Gorgels TG, Waarsing JH, de Wolf A, ten Brink JB, Loves WJ, Bergen AA. Dietary magnesium, not calcium, prevents vascular calcification in a mouse model for pseudoxanthoma elasticum. J Mol Med. 2010;88:467-475. doi: 10.1007/s00109-010-0596-3.
95. Kingman J, Uitto J, Li Q. Elevated dietary magnesium during pregnancy and postnatal life prevents ectopic mineralization in Enpp1 asj mice, a model for generalized arterial calcification of infancy. Oncotarget. 2017;8:38152-38160.
96. U.S. Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases; 2010.
97. Altura BM, Altura BT, Carella A, Gebrewold A, Murakawa T, Nishio A. Mg2+-Ca2+ interaction in contractility of vascular smooth muscle: Mg2+ versus organic calcium channel blockers on myogenic tone and agonist-induced responsiveness of blood vessels. Can J Physiol Pharmacol. 1987;65:729-745.
98. Howard AB, Alexander RW, Taylor WR. Effects of magnesium on nitric oxide synthase activity in endothelial cells. Am J Physiol. 1995;269(3 pt 1):C612-C618.
99. Zhang X, Li Y, Del Gobbo LC, Rosanoff A, Wang J, Zhang W, Song Y. Effects of magnesium supplementation on blood pressure: a meta-analysis of randomized double-blind placebo-controlled trials. Hypertension. 2016;68:324-333. doi: 10.1161/HYPERTENSIONAHA.116.07664.
100. McDonald SD, Lutsiv O, Dzaja N, Duley L. A systematic review of maternal and infant outcomes following magnesium sulfate for pre-eclampsia/ eclampsia in real-world use. Int J Gynaecol Obstet. 2012;118:90-96. doi: 10.1016/j.ijgo.2012.01.028.
101. Kyriazis J, Kalogeropoulou K, Bilirakis L, Smirnioudis N, Pikounis V, Stamatiadis D, Liolia E. Dialysate magnesium level and blood pressure. Kidney Int. 2004;66:1221-1231. doi: 10.1111/j.1523-1755.2004.00875.x.
102. Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-2038.
103. Reaven G. Insulin resistance and coronary heart disease in nondiabetic individuals. Arterioscler Thromb Vasc Biol. 2012;32:1754-1759. doi: 10.1161/ATVBAHA.111.241885.
104. Yahagi K, Kolodgie FD, Lutter C, Mori H, Romero ME, Finn AV, Virmani R. Pathology of human coronary and carotid artery atherosclerosis and vascular calcification in diabetes mellitus. Arterioscler Thromb Vasc Biol. 2017;37:191-204. doi: 10.1161/ATVBAHA.116.306256.
105. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P. Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension. 2007;49:1278-1284. doi: 10.1161/ HYPERTENSIONAHA.107.086942.
106. Slatopolsky E, Finch J, Denda M, Ritter C, Zhong M, Dusso A, MacDonald PN, Brown AJ. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest. 1996;97:2534-2540. doi: 10.1172/JCI118701.
107. Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, Rodriguez M. Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res. 1996;11:970-976. doi: 10.1002/jbmr.5650110714.
108. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int. 2007;71:31-38. doi: 10.1038/sj.ki.5002009.
109. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature. 2006;444:770-774. doi: 10.1038/nature05315.
110. Li SA, Watanabe M, Yamada H, Nagai A, Kinuta M, Takei K. Immunohistochemical localization of Klotho protein in brain, kidney, and reproductive organs of mice. Cell Struct Funct. 2004;29:91-99.
111. Krajisnik T, Olauson H, Mirza MA, Hellman P, Akerström G, Westin G, Larsson TE, Björklund P. Parathyroid Klotho and FGF-receptor 1 expression decline with renal function in hyperparathyroid patients with chronic kidney disease and kidney transplant recipients. Kidney Int. 2010;78:1024-1032. doi: 10.1038/ki.2010.260.
112. Hu MC, Shi M, Gillings N, Flores B, Takahashi M, Kuro-o M, Moe OW. Recombinant α-Klotho may be prophylactic and therapeutic for acute to chronic kidney disease progression and uremic cardiomyopathy. Kidney Int. 2017;91:1104-1114.
113. Schoppet M, Shroff RC, Hofbauer LC, Shanahan CM. Exploring the biology of vascular calcification in chronic kidney disease: what's circulating? Kidney Int. 2008;73:384-390. doi: 10.1038/sj.ki.5002696.
114. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827-833. doi: 10.1016/S0140-6736(03)12710-9.
115. Westenfeld R, Krueger T, Schlieper G, Cranenburg EC, Magdeleyns EJ, Heidenreich S, Holzmann S, Vermeer C, Jahnen-Dechent W, Ketteler M, Floege J, Schurgers LJ. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am J Kidney Dis. 2012;59:186-195. doi: 10.1053/j. ajkd.2011.10.041.
116. Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003;112:357-366. doi: 10.1172/JCI17202.
117. Luo G, Ducy P, McKee MD, Pinero GJ, Loyer E, Behringer RR, Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature. 1997;386:78-81. doi: 10.1038/386078a0.
118. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95:1046-1057. doi: 10.1161/01.RES.0000149165.99974.12.
119. Johnson K, Polewski M, van Etten D, Terkeltaub R. Chondrogenesis mediated by PPi depletion promotes spontaneous aortic calcification in NPP1-/-mice. Arterioscler Thromb Vasc Biol. 2005;25:686-691. doi: 10.1161/01.ATV.0000154774.71187.f0.
120. Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809. doi: 10.1172/JCI116391.
121. Shanahan CM, Cary NR, Salisbury JR, Proudfoot D, Weissberg PL, Edmonds ME. Medial localization of mineralization-regulating proteins in association with Mönckeberg's sclerosis: evidence for smooth muscle cell-mediated vascular calcification. Circulation. 1999;100:2168-2176.
122. Moe SM, Duan D, Doehle BP, O'Neill KD, Chen NX. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003;63:1003-1011. doi: 10.1046/j.1523-1755.2003.00820.x.
123. Pai AS, Giachelli CM. Matrix remodeling in vascular calcification associated with chronic kidney disease. J Am Soc Nephrol. 2010;21:1637-1640. doi: 10.1681/ASN.2010040349.
124. Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K, Morii H, Giachelli CM. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res. 2000;87:E10-E17.
125. Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty G, Giachelli CM. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001;89:1147-1154.
126. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, Jahnen-Dechent W, Weissberg PL, Shanahan CM. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15:2857-2867. doi: 10.1097/01. ASN.0000141960.01035.28.
127. Kapustin A, Shanahan CM. Emerging roles for vascular smooth muscle cell exosomes in calcification and coagulation. J Physiol. 2016;7:956-963.
128. Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, Jahnen-Dechent W, Shanahan CM. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005;16:2920-2930. doi: 10.1681/ ASN.2004100895.
129. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, Shanahan CM. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation. 2008;118:1748-1757. doi: 10.1161/ CIRCULATIONAHA.108.783738.
130. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, Schurgers LJ, Skepper JN, Proudfoot D, Mayr M, Shanahan CM. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res. 2011;109:e1-e12. doi: 10.1161/CIRCRESAHA.110.238808.
131. Aghagolzadeh P, Bachtler M, Bijarnia R, Jackson C, Smith ER, Odermatt A, Radpour R, Pasch A. Calcification of vascular smooth muscle cells is induced by secondary calciprotein particles and enhanced by tumor necrosis factor-α. Atherosclerosis. 2016;251:404-414. doi: 10.1016/j. atherosclerosis.2016.05.044.
132. Kapustin AN, Chatrou ML, Drozdov I, et al. Vascular smooth muscle cell calcification is mediated by regulated exosome secretion. Circ Res. 2015;116:1312-1323. doi: 10.1161/CIRCRESAHA.116.305012.
133. Pasch A, Farese S, Gräber S, Wald J, Richtering W, Floege J, Jahnen-Dechent W. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol. 2012;23:1744-1752. doi: 10.1681/ASN.2012030240.
134. Smith ER, Cai MM, McMahon LP, Pedagogos E, Toussaint ND, Brumby C, Holt SG. Serum fetuin-A concentration and fetuin-A-containing calciprotein particles in patients with chronic inflammatory disease and renal failure. Nephrology. 2013;18:215-221. doi: 10.1111/nep.12021.
135. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109:697-711. doi: 10.1161/ CIRCRESAHA.110.234914.
136. Kapustin A, Shanahan CM. Targeting vascular calcification: softeningup a hard target. Curr Opin Pharmacol. 2009;9:84-89. doi: 10.1016/j. coph.2008.12.004.
137. Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, Wiebe N, Muntner P. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality. Circulation. 2009;120:1784-1792. doi: 10.1161/CIRCULATIONAHA.109.851873.
138. Hutchison AJ. Oral phosphate binders. Kidney Int. 2009;75:906-914. doi: 10.1038/ki.2009.60.
139. O'Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V. Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphatemia. Lancet. 1986;1:880-882.
140. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol. 2006;1:697-703. doi: 10.2215/ CJN.00560206.
141. Morinière P, Vinatier I, Westeel PF, Cohemsolal M, Belbrik S, Abdulmassih Z, Hocine C, Marie A, Leflon P, Roche D. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uraemic patients on chronic haemodialysis: lack of deleterious effect on bone mineralisation. Nephrol Dial Transplant. 1988;3:651-656.
142. de Francisco AL, Leidig M, Covic AC, Ketteler M, Benedyk-Lorens E, Mircescu GM, Scholz C, Ponce P, Passlick-Deetjen J. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant. 2010;25:3707-3717. doi: 10.1093/ndt/gfq292.
143. Hutchison AJ, Wilkie M. Use of magnesium as a drug in chronic kidney disease. Clin Kidney J. 2012;5(suppl 1):i62-i70. doi: 10.1093/ndtplus/ sfr168.
144. De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D'Haese PC, Neven E. Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia. Kidney Int. 2013;83:1109-1117. doi: 10.1038/ki.2013.34.
145. Spiegel DM, Farmer B. Long-term effects of magnesium carbonate on coronary artery calcification and bone mineral density in hemodialysis patients: a pilot study. Hemodial Int. 2009;13:453-459. doi: 10.1111/j.1542-4758.2009.00364.x.
146. Ikee R, Toyoyama T, Endo T, Tsunoda M, Hashimoto N. Impact of sevelamer hydrochloride on serum magnesium concentrations in hemodialysis patients. Magnes Res. 2016;29:184-190. doi: 10.1684/ mrh.2016.0410.
147. Lee JS, Morrisett JD, Tung CH. Detection of hydroxyapatite in calcified cardiovascular tissues. Atherosclerosis. 2012;224:340-347. doi: 10.1016/j.atherosclerosis.2012.07.023.
148. Boistelle R, Lopez-Valero I, Abbona F. [Crystallization of calcium phosphate in the presence of magnesium]. Nephrologie. 1993;14:265-269.
149. Eanes ED, Posner AS. Kinetics and mechanism of conversion of noncrystalline calcium phosphate to hydroxyapatite. Trans N Y Acad Sci. 1965;28:233-241.
150. Termine JD, Peckauskas RA, Posner AS. Calcium phosphate formation in vitro. II. Effects of environment on amorphous-crystalline transformation. Arch Biochem Biophys. 1970;140:318-325.
151. Apfelbaum F, Mayer I, Rey C, Lebugle A. Magnesium in maturing synthetic apatite: a Fourier transform infrared analysis. J Cryst Growth. 1994;144:304-310.
152. Boskey AL, Posner AS. Magnesium stabilization of amorphous calcium phosphate: a kinetic study. Mater Res Bull. 1974;9:907-916.
153. Blumenthal NC, Betts F, Posner AS. Stabilization of amorphous calcium phosphate by Mg and ATP. Calcif Tissue Res. 1977;23:245-250.
154. Lomashvili KA, Cobbs S, Hennigar RA, Hardcastle KI, O'Neill WC. Phosphate-induced vascular calcification: role of pyrophosphate and osteopontin. J Am Soc Nephrol. 2004;15:1392-1401.
155. Villa-Bellosta R. On vascular calcification and plasma levels of pyrophosphate. Kidney Int. 2015;87:239. doi: 10.1038/ki.2014.309.
156. Jansen RS, Duijst S, Mahakena S, Sommer D, Szeri F, Váradi A, Plomp A, Bergen AA, Oude Elferink RP, Borst P, van de Wetering K. ABCC6-mediated ATP secretion by the liver is the main source of the mineralization inhibitor inorganic pyrophosphate in the systemic circulation-brief report. Arterioscler Thromb Vasc Biol. 2014;34:1985-1989. doi: 10.1161/ ATVBAHA.114.304017.
157. LeGeros RZ, Contiguglia SR, Alfrey AC. Pathological calcifications associated with uremia: two types of calcium phosphate deposits. Calcif Tissue Res. 1973;13:173-185.
158. Cheng PT, Grabher JJ, LeGeros RZ. Effects of magnesium on calcium phosphate formation. Magnesium. 1988;7:123-132.
159. Lagier R, Baud CA. Magnesium whitlockite, a calcium phosphate crystal of special interest in pathology. Pathol Res Pract. 2003;199:329-335. doi: 10.1078/0344-0338-00425.
160. Louvet L, Bazin D, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Characterisation of calcium phosphate crystals on calcified human aortic vascular smooth muscle cells and potential role of magnesium. PLoS One. 2015;10:e0115342. doi: 10.1371/journal.pone.0115342.
161. Schlieper G, Aretz A, Verberckmoes SC, et al. Ultrastructural analysis of vascular calcifications in uremia. J Am Soc Nephrol. 2010;21:689-696.
162. Kircelli F, Peter ME, Sevinc Ok E, Celenk FG, Yilmaz M, Steppan S, Asci G, Ok E, Passlick-Deetjen J. Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner. Nephrol Dial Transplant. 2012;27:514-521. doi: 10.1093/ndt/gfr321.
163. Bai Y, Zhang J, Xu J, Cui L, Zhang H, Zhang S, Feng X. Magnesium prevents β-glycerophosphate-induced calcification in rat aortic vascular smooth muscle cells. Biomed Rep. 2015;3:593-597. doi: 10.3892/ br.2015.473.
164. Salem S, Bruck H, Bahlmann FH, Peter M, Passlick-Deetjen J, Kretschmer A, Steppan S, Volsek M, Kribben A, Nierhaus M, Jankowski V, Zidek W, Jankowski J. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification. Am J Nephrol. 2012;35:31-39. doi: 10.1159/000334742.
165. Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, van Leeuwen FN, Touyz RM. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension. 2010;56:453-462. doi: 10.1161/HYPERTENSIONAHA.110.152058.
166. Louvet L, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant. 2013;28:869-878. doi: 10.1093/ndt/gfs520.
167. He Y, Yao G, Savoia C, Touyz RM. Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II. Circ Res. 2005;96:207-215. doi: 10.1161/01.RES.0000152967.88472.3e.
168. Herencia C, Rodríguez-Ortiz ME, Muñoz-Castañeda JR, Martinez-Moreno JM, Canalejo R, Montes de Oca A, Díaz-Tocados JM, Peralbo-Santaella E, Marín C, Canalejo A, Rodriguez M, Almaden Y. Angiotensin II prevents calcification in vascular smooth muscle cells by enhancing magnesium influx. Eur J Clin Invest. 2015;45:1129-1144. doi: 10.1111/eci.12517.
169. Montes de Oca A, Guerrero F, Martinez-Moreno JM, Madueño JA, Herencia C, Peralta A, Almaden Y, Lopez I, Aguilera-Tejero E, Gundlach K, Büchel J, Peter ME, Passlick-Deetjen J, Rodriguez M, Muñoz-Castañeda JR. Magnesium inhibits Wnt/β-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One. 2014;9:e89525. doi: 10.1371/journal.pone.0089525.
170. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115:1210-1220. doi: 10.1172/ JCI24140.
171. Brigant B, Metzinger-Le Meuth V, Massy ZA, et al. Serum microRNAs are altered in various stages of chronic kidney disease: a preliminary study. Clin Kidney J. 2017;10:30-37.
172. Cui RR, Li SJ, Liu LJ, Yi L, Liang QH, Zhu X, Liu GY, Liu Y, Wu SS, Liao XB, Yuan LQ, Mao DA, Liao EY. MicroRNA-204 regulates vascular smooth muscle cell calcification in vitro and in vivo. Cardiovasc Res. 2012;96:320-329. doi: 10.1093/cvr/cvs258.
173. Louvet L, Metzinger L, Büchel J, Steppan S, Massy ZA. Magnesium attenuates phosphate-induced deregulation of a microRNA signature and prevents modulation of Smad1 and osterix during the course of vascular calcification. Biomed Res Int. 2016;2016:7419524. doi: 10.1155/2016/7419524.
174. Leidi M, Dellera F, Mariotti M, Maier JA. High magnesium inhibits human osteoblast differentiation in vitro. Magnes Res. 2011;24:1-6. doi: 10.1684/mrh.2011.0271.
175. Yue J, Jin S, Li Y, Zhang L, Jiang W, Yang C, Du J. Magnesium inhibits the calcification of the extracellular matrix in tendon-derived stem cells via the ATP-P2R and mitochondrial pathways. Biochem Biophys Res Commun. 2016;478:314-322. doi: 10.1016/j.bbrc.2016.06.108.
176. Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL. Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res. 2000;87:1055-1062.
177. Rodenbeck SD, Zarse CA, McKenney-Drake ML, et al. Intracellular calcium increases in vascular smooth muscle cells with progression of chronic kidney disease in a rat model. Nephrol Dial Transplant. 2017;32:450-458.
178. Iseri LT, French JH. Magnesium: nature's physiologic calcium blocker. Am Heart J. 1984;108:188-193.
179. Zhang J, Berra-Romani R, Sinnegger-Brauns MJ, Striessnig J, Blaustein MP, Matteson DR. Role of Cav1.2 L-type Ca2+ channels in vascular tone: effects of nifedipine and Mg2+. Am J Physiol Heart Circ Physiol. 2007;292:H415-H425. doi: 10.1152/ajpheart.01214.2005.
180. Hénaut L, Boudot C, Massy ZA, Lopez-Fernandez I, Dupont S, Mary A, Drüeke TB, Kamel S, Brazier M, Mentaverri R. Calcimimetics increase CaSR expression and reduce mineralization in vascular smooth muscle cells: mechanisms of action. Cardiovasc Res. 2014;101:256-265. doi: 10.1093/cvr/cvt249.
181. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993;366:575-580. doi: 10.1038/366575a0.
182. Riccardi D. Cell surface, Ca2+(cation)-sensing receptor(s): one or many? Cell Calcium. 1999;26:77-83. doi: 10.1054/ceca.1999.0066.
183. Ruat M, Snowman AM, Hester LD, Snyder SH. Cloned and expressed rat Ca2+-sensing receptor. J Biol Chem. 1996;271:5972-5975.
184. Rodríguez-Ortiz ME, Canalejo A, Herencia C, Martínez-Moreno JM, Peralta-Ramírez A, Perez-Martinez P, Navarro-González JF, Rodríguez M, Peter M, Gundlach K, Steppan S, Passlick-Deetjen J, Muñoz-Castañeda JR, Almaden Y. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration. Nephrol Dial Transplant. 2014;29:282-289. doi: 10.1093/ndt/gft400.
185. Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, Vizard TN, Sage AP, Martin D, Ward DT, Alexander MY, Riccardi D, Canfield AE. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res. 2009;81:260-268. doi: 10.1093/cvr/cvn279.
186. Schurgers LJ, Spronk HM, Skepper JN, Hackeng TM, Shanahan CM, Vermeer C, Weissberg PL, Proudfoot D. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J Thromb Haemost. 2007;5:2503-2511. doi: 10.1111/j.1538-7836.2007.02758.x.
187. Molostvov G, Hiemstra TF, Fletcher S, Bland R, Zehnder D. Arterial expression of the calcium-sensing receptor is maintained by physiological pulsation and protects against calcification. PLoS One. 2015;10:e0138833. doi: 10.1371/journal.pone.0138833.
188. Mendoza FJ, Martinez-Moreno J, Almaden Y, Rodriguez-Ortiz ME, Lopez I, Estepa JC, Henley C, Rodriguez M, Aguilera-Tejero E. Effect of calcium and the calcimimetic AMG 641 on matrix-Gla protein in vascular smooth muscle cells. Calcif Tissue Int. 2011;88:169-178. doi: 10.1007/s00223-010-9442-4.
189. Alesutan I, Tuffaha R, Auer T, et al. Inhibition of osteo/chondrogenic transformation of vascular smooth muscle cells by MgCl2 via calciumsensing receptor. J Hypertens. 2016;35:523-532.